thanks @ChickenCrimpy for the post AND the link. significant for me is that, of the thousands of reviewed studies, Mesoblast DREAM-HF was selected as one of the top five for potential impact. and when you read the short write ups on each of the five studies, Mesoblast stands head and shoulders above the rest. In my view there is nothing that will be able to hold this back. Its not like the tiny number of patients impacted by pediatric aGVHD where the FDA could sweep it under the rug. For heart failure it is a whole world of hundreds of thousands of cases impacted annually. the cat is out of the bag.
thanks @ChickenCrimpy for the post AND the link. significant for...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.015(1.40%) |
Mkt cap ! $1.238B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.12 | $1.08 | $11.51M | 10.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17804 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 230637 | 5 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.015 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.12 | $1.08 | 1937390 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| MSB (ASX) Chart |